Dimitrios Strepkos

Dimitrios Strepkos

Auto-generated profile, based on publicly available information

Dimitrios Strepkos

Minneapolis Heart Institute and Minneapolis Heart Institute Foundation Abbott Northwestern Hospital Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Cancer Research
Verified
Journal Article
Closed access
PDF file
DSDimitrios Strepkos
Dimitrios Strepkos
MMMarkouli Mariam
Markouli Mariam
AKAlexia Klonou
Alexia Klonou
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou
Christina PiperiChristina Piperi
Christina Piperi
Epigenetic regulation of gene expression has been ultimately linked to cancer development, with posttranslational histone modifications representing attractive targets for disease monitoring and therapy. Emerging data have demonstrated histone lysine (K) methylation by methyltransferase SETDB1 as a common denominator of gene regulation in several cancer types. SETDB1 reversibly catalyzes the di- and trimethylation of histone 3 (H3) K9 in euchromatic regions of chromosomes, inhibiting gene transcription within these regions and promoting a switch from euchromatic to heterochromatic states. Recent studies have implicated aberrant SETDB1 activity in the development of various types of cancers, including brain, head and neck, lung, breast, gastrointestinal, ovarian, endometrial and prostate cancer, mesothelioma, melanoma, leukemias, and osteosarcoma. Although its role has not been fully elucidated in every case, most data point toward a pro-oncogenic potential of SETDB1 via the downregulation of critical tumor-suppressive genes. Less commonly, however, SETDB1 can also acquire a tumor-suppressive role, depending on cancer type and stage. Here we provide an updated overview of the cellular and molecular effects underlying SETDB1 activity in cancer development and progression along with current targeting strategies in different cancer types, with promising effects either as a standalone therapy or in conjunction with other therapeutic agents.

24 October 2019 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
DSDimitrios Strepkos
Dimitrios Strepkos
MMMariam Markouli
Mariam Markouli
AKAlexia Klonou
Alexia Klonou
Christina PiperiChristina Piperi
Christina Piperi
Athanasios G. PapavassiliouAthanasios G. Papavassiliou
Athanasios G. Papavassiliou

1 May 2021 in Progress in Neurobiology
Verified
Journal Article
Closed access
MMMarkouli Mariam
Markouli Mariam
DSDimitrios Strepkos
Dimitrios Strepkos
SCSARANTIS CHLAMYDAS
SARANTIS CHLAMYDAS
Christina PiperiChristina Piperi
Christina Piperi

3 February 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
DSDimitrios Strepkos
Dimitrios Strepkos
MAMichaella Alexandrou
Michaella Alexandrou
DMDeniz Mutlu
Deniz Mutlu
PCPedro E. P. Carvalho
Pedro E. P. Carvalho
OSOzgur S. Ser
Ozgur S. Ser
EBEmmanouil Brilakis
Emmanouil Brilakis

24 October 2024 in The American Journal of Cardiology
Verified
Journal Article
Closed access
DSDimitrios Strepkos
Dimitrios Strepkos
MAMichaella Alexandrou
Michaella Alexandrou
DMDeniz Mutlu
Deniz Mutlu
PCPedro E.P. Carvalho
Pedro E.P. Carvalho
OKOleg Krestyaninov
Oleg Krestyaninov
EBEmmanouil Brilakis
Emmanouil Brilakis

13 October 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
DMDeniz Mutlu
Deniz Mutlu
ARAthanasios Rempakos
Athanasios Rempakos
DSDimitrios Strepkos
Dimitrios Strepkos
PCPedro E. P. Carvalho
Pedro E. P. Carvalho
MAMichaella Alexandrou
Michaella Alexandrou
SGSevket Gorgulu
Sevket Gorgulu